Sagimet Biosciences (SGMT) Q2 2026 earnings summary

Executive summary

• Denifanstat met all endpoints in a Phase 3 acne trial in China and is advancing to a US Phase 3 trial planned for H2 2026, with long-term safety and efficacy demonstrated at 52 weeks.

• TVB-3567, a second FASN inhibitor, is in a Phase 1 trial for acne, with a Phase 2 trial anticipated before end of 2026.

• Strategic focus has shifted to dermatology, prioritizing capital allocation to this area.

• Combination program of denifanstat and resmetirom for MASH is Phase 2-ready, pending non-dilutive financing.

• Hosted a Key Opinion Leader event and presented new data at major scientific meetings.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $257.6 million as of June 30, 2026, up from $116.5 million at year-end 2025, primarily due to a $163.9 million net raise in April 2026.

• Net loss for Q2 2026 was $14.0 million, compared to $10.4 million in Q2 2025; net loss for the first half of 2026 was $24.8 million, down from $28.7 million in the prior year period.

• Research and development expenses rose 59% year-over-year in Q2 2026 to $11.5 million, driven by TVB-3567 clinical trial costs and increased stock-based compensation.

• General and administrative expenses decreased 8% year-over-year in Q2 2026 to $4.3 million, mainly due to lower consulting costs.

• Completed $175.0 million equity financing in April 2026.

Outlook and guidance

• Denifanstat Phase 3 trial in moderate to severe acne to begin in the second half of 2026, with data readout and NDA submission expected within current funding.

• TVB-3567 Phase 2 trial in acne planned after Phase 1 completion and regulatory consultation.

• No further clinical development in MASH will occur until non-dilutive financing is secured.

• Research and development and general and administrative expenses are expected to increase as pipeline advances.

• Development of a topical FASN inhibitor for acne is planned.